Skip to main content

Table 2 Baseline characteristics of patients in each set of treatment sequences

From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

  FF sequences
(n= 147)
FP sequences
(n= 43)
Total
(n= 190)
Age (years) 31.4 (15.30) 35.2 (16.03) 32.3 (15.51)
Range 12-68 12-76 12-76
Females, n (%) 87 (59) 21 (49) 108 (57)
Race (%)    
   White 90 (61) 22 (51) 112 (59)
African American/
African heritage
50 (34) 20 (47) 70 (37)
   Other 7 (5) 1 (2) 8 (4)
History of atopy, n (%) 93 (63) 27 (63) 120 (63)
Lung function at screening    
   Reversibility of FEV1 (%) 27.20 (13.667) 27.52 (16.449) 27.27 (14.298)
   Reversibility of FEV1 (ml) 608.2 (304.64) 591.4 (367.47) 604.4 (318.98)
Lung function at study baseline    
   Pre-bronchodilator FEV1 (L) 2.296 (0.6176) 2.293 (0.6990) 2.296 (0.6350)
Pre-bronchodilator FEV1
(% predicted)
69.85 (9.704) 67.73 (11.204) 69.37 (10.071)
  1. Values are mean and standard deviation unless stated. Data shown are for the ITT population.
  2. FEV1 = forced expiratory volume in 1 second; FF = fluticasone furoate;
  3. FP = fluticasone propionate